Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

thorium Th 227 anetumab corixetan

A radioimmunoconjugate consisting of anetumab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein mesothelin, conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 anetumab corixetan, the anetumab moiety binds to the tumor-associated antigen (TAA) mesothelin, delivering a cytotoxic dose of alpha radiation to cells expressing mesothelin.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:227Th anetumab corixetan
thorium Th 227 monoclonal antibody BAY2287411
thorium-227-labeled anetumab
thorium-227-labeled antibody-chelator conjugate BAY2287411
Code name:BAY 2287411
BAY2287411
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search